The Complete Wegovy vs Mounjaro Comparison Guide
Wegovy or Mounjaro for Weight Loss: Understanding the Key Differences
When comparing Wegovy or Mounjaro for weight loss, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, whilst Mounjaro contains tirzepatide, a dual agonist targeting both GIP and GLP-1 receptors. This dual-action approach means Mounjaro works on two hormone pathways simultaneously, potentially offering a different therapeutic profile for weight management alongside a reduced-calorie diet and increased physical activity.
Both prescription-only medicines require careful dose escalation and ongoing clinical supervision through our GPhC-registered pharmacy (#9012878). Wegovy follows a 5-step escalation protocol (0.25mg to 2.4mg over 16 weeks), whilst Mounjaro uses 6 dose levels (2.5mg to 15mg). Neither approach is inherently superior — your prescriber will recommend the most appropriate treatment based on your individual clinical assessment, medical history, and response to initial therapy.
Wegovy or Mounjaro for Weight Loss: Pricing and Value Comparison
Understanding the cost implications of Wegovy or Mounjaro for weight loss helps inform your treatment decision. Wegovy starter doses begin at £79.99 (0.25mg) with new customer code FIRST40, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for maintenance 2.4mg doses. Our bundled options include the Intro Duo (0.25mg & 0.5mg) for £169.99, providing your first 8 weeks of treatment with convenient single-order procurement.
Mounjaro pricing follows a different structure, with costs varying across its 6-dose escalation schedule. Both treatments represent significant monthly investments, but our bundle packages provide supply continuity without repeated ordering. Returning customers benefit from discount code DOSE25, whilst our 3-pen bundles like the Ultimate Stability Trio (£649.99 for three 2.4mg Wegovy pens) ensure maintenance supply security for established patients.
Clinical Evidence: Wegovy or Mounjaro for Weight Loss Trials
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the landmark STEP 1 trial (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent efficacy across different patient populations, including those with type 2 diabetes and varying baseline characteristics. These results positioned semaglutide as a significant advancement in weight management therapy when used as prescribed.
Mounjaro's clinical programme showed its own efficacy profile in the SURMOUNT trials, though direct head-to-head comparisons between Wegovy or Mounjaro for weight loss remain limited due to different trial designs and patient populations. Both treatments demonstrated superiority over placebo when combined with lifestyle interventions, but individual response varies significantly between patients, making personalised prescriber guidance essential for optimal outcomes.
How Wegovy Works for Weight Loss Management
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a natural hormone released by your intestines after eating. This mechanism triggers several weight-management pathways: it slows gastric emptying, meaning food remains in your stomach longer, promoting sustained satiety between meals. Additionally, Wegovy acts on appetite centres in your brain, potentially reducing food cravings and the psychological drive to eat. The once-weekly FlexTouch pen delivers consistent therapeutic levels, supporting appetite regulation throughout the week. These biological effects work synergistically with reduced-calorie diet and increased physical activity to support meaningful weight loss in appropriate patients. Clinical supervision ensures optimal dose titration and monitoring for potential side effects during treatment.
Ordering Wegovy or Mounjaro for Weight Loss Through EverydayMeds
Starting your Wegovy or Mounjaro for weight loss journey begins with our comprehensive 3-minute online clinical assessment, designed to capture essential medical history, current medications, and treatment goals. Your assessment undergoes thorough review by our qualified prescribers, typically completed within 3 working days, or within 24 hours using our express service option. Once approved, your prescription-only medicine ships via next-day delivery using specialised cold-chain logistics, ensuring temperature integrity throughout transit. Our pharmacy team coordinates your dose escalation schedule, sending timely reminders for follow-up orders and monitoring your treatment progression. This integrated approach combines clinical expertise with logistical excellence, supporting your long-term weight management success.
Storage and Practical Considerations for Weight Loss Treatments
Wegovy offers superior storage flexibility compared to Mounjaro, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, versus Mounjaro's 21-day limit. This advantage proves particularly valuable for frequent travellers or those with unpredictable schedules who cannot ensure consistent refrigeration access. Both treatments require initial storage at 2–8°C and utilise pre-filled injection pens designed for subcutaneous self-administration. The FlexTouch pen system (Wegovy) and KwikPen system (Mounjaro) both feature dose counters and safety mechanisms to prevent accidental overdosing. Proper injection technique training and rotation of injection sites help minimise local reactions and ensure optimal drug absorption throughout your treatment course.
Wegovy or Mounjaro for Weight Loss: Personalised Treatment Selection
Choosing between Wegovy or Mounjaro for weight loss requires individualised clinical assessment considering your medical history, previous weight loss attempts, concurrent medications, and personal preferences regarding injection frequency and storage requirements. Some patients respond more favourably to GLP-1 monotherapy (Wegovy), whilst others may benefit from dual-hormone pathway activation (Mounjaro). Factors such as diabetes status, cardiovascular risk profile, and tolerance to gastrointestinal side effects influence treatment selection.
Your prescriber evaluates these variables alongside practical considerations like travel requirements, storage capabilities, and cost preferences to recommend the most appropriate therapy. Both treatments require long-term commitment — clinical data suggests weight regain occurs when treatment discontinues, making sustainable treatment selection crucial for lasting success in weight management alongside continued lifestyle modifications.
Start Your Weight Loss Journey With Expert Support Today
EverydayMeds provides comprehensive access to both Wegovy or Mounjaro for weight loss, eliminating the need to compromise on treatment options due to pharmacy limitations. Our clinical team supports your journey from initial assessment through ongoing dose optimisation, ensuring you receive the most appropriate therapy for your individual circumstances. New customers apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 for continued savings on their weight management investment. Complete your clinical assessment today to begin your professionally supervised weight loss programme with the confidence that comes from expert clinical oversight and premium pharmaceutical care. Your journey towards sustainable weight management starts with a single consultation — take that step today.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
